Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Technologies Moves a Step Closer to Canadian COVID Vaccine

Trevor Abes  February 7, 2022

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

GlobeNewswire February 7, 2022

Theralase Expands Intellectual Property Portfolio

GlobeNewswire December 9, 2021

Theralase Releases 3Q21 Financial Statements and Newsletter

GlobeNewswire November 29, 2021

Theralase Announces Leadership Reorganization

GlobeNewswire November 15, 2021

Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter

GlobeNewswire August 30, 2021

Theralase Announces Leadership Transition

GlobeNewswire August 19, 2021

Theralase Releases Q12021 Interim Financial Statements

GlobeNewswire May 28, 2021

Theralase Release FY2020 Audited Financial Statements

Accesswire April 28, 2021

Theralase(R) Releases Quarterly Newsletter

Accesswire April 27, 2021

Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine

Accesswire April 9, 2021

Theralase Launches Anti-Cancer Therapy Research Centre

Accesswire March 29, 2021

Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire March 25, 2021

Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire February 24, 2021

Theralase(R) Releases Quarterly Newsletter

Accesswire February 1, 2021

Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire January 27, 2021

Theralase Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire January 25, 2021

Theralase Expands Intellectual Property Portfolio

Accesswire January 22, 2021

Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire January 20, 2021

Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Accesswire January 19, 2021